Market accessOfficial

AIFA publishes Class A and H medicine tables current to 30 June 2026

🇮🇹 AIFA · Mon 26 Oct 2026

Italy's medicines agency has issued updated reference tables of NHS-dispensed Class A and Class H products, supporting prescribing by active substance and noting an equivalence code change for amiodarone injection.

The Italian Medicines Agency (AIFA) has released its Class A and Class H medicine tables, reflecting the market position as of 30 June 2026. They list products dispensed by the Italian National Health Service, with Class A ordered by active substance and Class H by trade name.

AIFA says the tables exist to support prescribing by active substance, as provided for in Article 15, paragraph 11-bis, of Decree-Law 95 of 6 July 2012, as converted into law. The tables are available to all healthcare professionals and are described as a technical tool.

They cover medicines on AIFA's transparency list, products still under patent protection, and products whose patent protection has expired but for which substitution is not permitted. The agency stresses that, unlike the transparency lists, the tables grouped by active substance do not set maximum reimbursement prices. Every pack of a medicinal product marketed on 30 June 2026 is included.

One specific change is flagged in the Class H table for prescribing by active substance. To preserve historical data on equivalence groups, the equivalence code for the group amiodarone 150 mg/3 ml, five units for parenteral use, has been altered from "ADT" to "44°". The notice names Amiodar (AIC 022033029) and Cordarone (AIC 025035027) as members of the group. The source text is cut off at this point, so the remaining explanation of their classification history is not available.

What it means for your team

  • Prescribers and pharmacy teams in Italy should use the 30 June 2026 tables as the current reference for Class A and H classification and active-substance prescribing.
  • Market-access teams should note that the active-substance groupings do not set maximum reimbursement prices; the transparency lists remain the reference for that purpose.
  • Teams whose systems map equivalence groups should check the amiodarone 150 mg/3 ml parenteral group, where the code changed from "ADT" to "44°".

Official source: AIFA ↗

Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.

More Market access All →